FSD Pharma Inc. | WebDisclosure

Basculer en Français

10165	Companies
208920	Keywords
138995	Articles
110724	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 1 month ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 1 month ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 1 month ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 1 month ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 1 month ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 1 month ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 04/07/2026 at 12:00, 48 minutes ago

Banyan Gold Continues to Intersect High-Grade Gold in Powerline, AurMac Deposit, Yukon, Canada
Published on 04/07/2026 at 09:30, 3 hours 18 minutes ago

Formation Metals to Host Live Investor Webinar on the N2 Gold Project to Discuss Phase 1 Drill Results, including 1.75 g/t Au over 30.4 Metres, and Maiden Resource Estimate Following Fully Funded 30,000-Metre Program
Published on 04/07/2026 at 09:05, 3 hours 43 minutes ago

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
Published on 04/07/2026 at 09:01, 3 hours 47 minutes ago

Apex Drills 81.6 m of 2.02% REO, including 50.9 m of 2.40% REO, Extending Strike Length of Main Body, with Highly Enriched NdPr Zone at Rift
Published on 04/07/2026 at 08:00, 4 hours 48 minutes ago

Caledonia Mining Corporation Plc: Encouraging Results From Deep Level Drilling at Blanket Mine

View all ACCESSWIRE

EQS Group

Published on 04/07/2026 at 12:19, 28 minutes ago

Aroundtown SA: Release of a capital market information
Published on 04/07/2026 at 12:18, 29 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 04/07/2026 at 12:13, 35 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 04/07/2026 at 12:00, 48 minutes ago

Linde Announces First Quarter 2026 Earnings and Conference Call Schedule
Published on 04/07/2026 at 11:50, 58 minutes ago

4finance announces early redemption of its EUR Notes due October 2026

Les Echos

Published on 04/07/2026 at 12:00, 48 minutes ago

Disclosure of shares outstanding and voting rights - 07.04.2026
Published on 04/07/2026 at 12:00, 48 minutes ago

Déclaration nombre d'actions et droits de vote - 07.04.2026
Published on 04/07/2026 at 08:30, 4 hours 18 minutes ago

Edenred achieves CDP “A” rating and joins the ranks of global leaders in climate action
Published on 04/07/2026 at 08:30, 4 hours 18 minutes ago

Edenred obtient la note « A » au CDP et rejoint les leaders mondiaux engagés pour le climat
Published on 04/07/2026 at 08:00, 4 hours 48 minutes ago

Global Agreement Announced at G7 One Health Summit to Accelerate Access to Diagnostics and Responses to Rising Health Threats

View all LES ECHOS COMFI WIRE